ABUS
Strong BuyUnloved QualityAI neutralArbutus Biopharma Corporation · Healthcare · United States · $961M cap · $28.2M/day traded
$4.15 -1.7% · close 12 Oct · scored 14 Oct
StockRank down 2.2 since 13 Oct.
Unloved Quality: Strong and cheap; the market has not turned yet.
As of 14 Oct 2026, MoatMap's StockRank for Arbutus Biopharma Corporation (ABUS) is 81/100, ranked against 24,000+ stocks in 35 markets (Quality 70, Value 61, Momentum 45, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Arbutus Biopharma is a biotechnology company focused on hepatitis B and on patent litigation over lipid nanoparticle technology. It has launched a modified Dutch auction tender offer to repurchase up to US$230 million of shares at US$5.00 to US$5.75, which lifted the shares. The value of the company depends heavily on legal outcomes and clinical progress that are hard to assess from the outside.
ABOUT ARBUTUS BIOPHARMA CORPORATION
Read
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapeutics for chronic hepatitis B virus (HBV) infection. The company's competitive advantage stems from its proprietary pipeline of differentiated drug candidates, including RNA interference (RNAi) and capsid assembly inhibitors, which target multiple stages of the HBV lifecycle and address a significant global unmet medical need within a specialized therapeutic area.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.0M | 39.0M | 18.1M | 6.2M | 14.1M | 6.4% | 181.7M | 252.8M | 5.7M | -36.4% |
| EPS | -0.83 | -0.46 | -0.44 | -0.38 | -0.17 | — | 0.79 | 1.03 | -0.11 | — |
| Shares | 145.0M | 157.5M | 169.9M | 190.0M | 192.5M | +32.8% | 153.3M | — | — | — |
| Debt | 2.6M | 2.2M | 1.8M | 1.3M | 0.7M | -26.9% | 3.6M | — | — | — |
| Equity | 169.4M | 136.9M | 106.0M | 97.4M | 76.6M | -18.0% | — | — | — | — |
| Op CF | -67.5M | -35.4M | -85.9M | -64.8M | -39.6M | — | -24.6M | — | — | — |
| Inv CF | -12.7M | -74.9M | 50.8M | 22.9M | 15.6M | — | — | — | — | — |
| Fin CF | 137.2M | 31.8M | 30.6M | 52.0M | 5.7M | — | — | — | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Swung more than 57% of stocks we rank over the past year (46% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ABUS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ABUS | Arbutus Biopharma Corporation(you) | $961M | 81 | Strong Buy |
| MDXG | MiMedx Group, Inc. | $696M | 74 | Buy |
| ZVRA | Zevra Therapeutics, Inc. | $672M | 92 | Strong Buy |
| RIGL | Rigel Pharmaceuticals, Inc. | $899M | 98 | Strong Buy |
| INVA | Innoviva, Inc. | $1.5B | 93 | Strong Buy |
| ADMA | ADMA Biologics, Inc. | $2.2B | 73 | Buy |
| CRMD | CorMedix Inc. | $599M | 98 | Strong Buy |
| MGTX | MeiraGTx Holdings plc | $1.1B | 57 | Hold |
| AGEN | Agenus Inc. | $379M | 70 | Buy |
| PBYI | Puma Biotechnology, Inc. | $479M | 98 | Strong Buy |
Peer medians: ROE -26.1% · P/E 29.0x · Gross margin 64.2%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.